血必净注射液治疗重型新型冠状病毒肺炎的多中心前瞻性队列研究
该多中心前瞻性队列研究纳入15个省市28家定点医院ICU的144例重型COVID-19患者(PSI风险III-V级),按是否接受血必净分为血必净组和标准治疗组各72例。血必净组在标准治疗基础上于入ICU 12小时内使用血必净100 mL/次、每日2次,最短疗程1天。结果显示血必净组第8天PSI风险分级改善率56.9% vs 20.8%(差值36.1%,95%CI 21.3%-50.9%,P<0.01),第28天出院率66.7% vs 22.2%(P<0.01),28天生存率91.7% vs 81.9%(P<0.01),不良事件发生率无显著差异。
要点
- 重型COVID-19 ICU患者,标准治疗基础上入ICU 12小时内加用血必净100 mL/次、每日2次,最短1天,可提高第8天PSI风险分级改善率(56.9% vs 20.8%,P<0.01)。
- 血必净组第28天出院率66.7%(48/72)vs 标准治疗组22.2%(16/72),P<0.01;28天生存率91.7%(66/72)vs 81.9%(59/72),P<0.01。
- 血必净组第8天PSI评分、SOFA评分和PaO2/FiO2均显著优于标准治疗组(PSI差值-24.5,95%CI -34.9至-14.1;SOFA差值-3.5,95%CI -5.0至-2.0;PaO2/FiO2差值100.9 mmHg,95%CI 65.3至136.5,均P<0.01)。
- 两组抗病毒药、抗生素、抗凝药和血管活性药联用情况无显著差异;不良事件发生率41.7% vs 43.1%(P>0.05),未报告血必净严重不良事件或不良反应。
- 研究为多中心前瞻性队列,非随机对照,样本量144例,结论需RCT进一步验证;适用人群为PSI风险III-V级的重型COVID-19 ICU患者。
适用人群与场景
- 2020年1月至3月中国15个省市28家COVID-19定点医院ICU收治的成年COVID-19患者,连续筛查276例,最终分析144例符合PSI风险III-V级的重型患者。
- 排除标准原文未提及;研究场景为ICU,病情阶段为入住ICU时。
诊断标准与关键阈值
- 纳入分析标准:COVID-19重型患者且PSI风险分级为III-V级。
- PSI风险分级改善定义为第8天PSI风险评级较基线改善,原文未给出具体改善定义细则。
处置流程与药物剂量
- 所有患者按国家卫生健康委员会发布的COVID-19标准治疗方案治疗,包括抗病毒、呼吸支持、循环支持和对症治疗等常规医疗措施。
- 血必净组在标准治疗基础上,于入ICU 12小时内开始使用血必净注射液,100 mL/次,每日2次,最短给药疗程1天;原文未提及给药途径、最长疗程和目标值。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:多中心前瞻性队列研究;样本量:连续筛查276例,分析144例(血必净组72例,标准治疗组72例);中心数:15个省市28家定点医院。
- 人群:成年COVID-19 ICU患者,PSI风险III-V级;血必净组平均年龄(63.5±10.9)岁,男性70.8%(51/72);标准治疗组平均年龄(65.7±7.9)岁,男性75.0%(54/72)。
- 干预与对照:血必净组在标准治疗基础上加用血必净100 mL/次、每日2次(入ICU 12小时内开始,最短1天);标准治疗组仅标准治疗。
- 主要终点:第8天PSI风险分级改善率血必净组56.9%(41/72)vs 标准治疗组20.8%(15/72),组间差值36.1%(95%CI 21.3%-50.9%),P<0.01。
- 关键次要终点:第8天PSI评分83.7±34.8 vs 108.2±25.6,差值-24.5(95%CI -34.9至-14.1);SOFA评分2.0(1.0,4.0)vs 7.0(4.0,10.0),差值-3.5(95%CI -5.0至-2.0);PaO2/FiO2 289.4±111.6 mmHg vs 188.5±98.1 mmHg,差值100.9 mmHg(95%CI 65.3至136.5),均P<0.01。
- 第28天出院率血必净组66.7%(48/72)vs 22.2%(16/72),P<0.01;28天生存率91.7%(66/72)vs 81.9%(59/72),P<0.01。
- 不良事件发生率血必净组41.7%(30/72)vs 43.1%(31/72),P>0.05;未报告血必净相关严重不良事件和不良反应。
证据类型、等级与局限
- 证据类型:多中心前瞻性队列研究(非随机对照)。
- 局限:非随机分组,样本量144例,可能存在选择偏倚和混杂;原文未提及盲法;结论需随机对照试验进一步验证。
对床旁实践的改变
- 对于PSI风险III-V级的重型COVID-19 ICU患者,可考虑在标准治疗基础上于入ICU 12小时内加用血必净100 mL/次、每日2次,最短1天,以改善第8天PSI风险分级和第28天出院率。
- 该研究为非随机队列,不能将血必净视为所有重型COVID-19患者的强制推荐;适用人群限于PSI风险III-V级,不适用于非重型或PSI风险I-II级患者(原文未纳入)。
- 常见陷阱:不能将研究方案中的血必净剂量和疗程外推为其他人群或其他疾病的通用推荐;需注意原文未报告给药途径。
指南或共识出处
- 原文未提及指南或共识名称;研究引用国家卫生健康委员会发布的COVID-19标准治疗方案。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate the effect of Xuebijing injection on the improvement of pneumonia severity index (PSI) and prognosis in patients with severe coronavirus disease 2019 (COVID-19).
METHODS: A multicenter prospective cohort study was designed. Adult patients with COVID-19 admitted to the intensive care unit (ICU) of 28 designated COVID-19 hospitals in 15 provinces and cities of China from January to March 2020 were enrolled. All patients were treated according to the standard treatment plan of COVID-19 issued by the National Health Commission of the People's Republic of China. They were divided into Xuebijing group and standard treatment group according to whether they received Xuebijing injection or not. In the standard treatment group, routine medical care measures such as antiviral, respiratory support, circulatory support and symptomatic treatment were taken. In the Xuebijing group, on the basis of standard treatment, Xuebijing was used within 12 hours of admission to the ICU, 100 mL each time, twice daily. The minimum duration of Xuebijing administration was 1 day. The improvement rate of PSI risk rating on the 8th day and clinical outcome on the 28th day were recorded.
RESULTS: A total of 276 COVID-19 patients were screened continuously, and the data of 144 severe patients who met PSI risk rating III-V were analyzed. Seventy-two cases were involved each in standard treatment group and Xuebijing group. The average age of the standard treatment group and Xuebijing group were (65.7±7.9) years old and (63.5±10.9) years old, and male accounted for 75.0% (54/72) and 70.8% (51/72), respectively. There were no significant differences in general conditions, comorbidities, PSI risk rating and score, sequential organ failure assessment (SOFA) score, oxygenation index (PaO2/FiO2), respiratory support mode and other baseline indicators between the two groups. Compared with the standard treatment group, the improvement rate of PSI risk rating in Xuebijing group on the 8th day after admission was significantly improved [56.9% (41/72) vs. 20.8% (15/72), between-group difference and 95% confidence interval (95%CI) was 36.1% (21.3% to 50.9%), P < 0.01], PSI score, SOFA score and PaO2/FiO2 were significantly improved [PSI score: 83.7±34.8 vs. 108.2±25.6, between-group difference (95%CI) was -24.5 (-34.9 to -14.1); SOFA score: 2.0 (1.0, 4.0) vs. 7.0 (4.0, 10.0), between-group difference (95%CI) was -3.5 (-5.0 to -2.0); PaO2/FiO2 (mmHg, 1 mmHg = 0.133 kPa): 289.4±111.6 vs. 188.5±98.1, between-group difference (95%CI) was 100.9 (65.3 to 136.5); all P < 0.01]. The 28-day discharge rate of Xuebijing group was 44.5% higher than that of standard treatment group [66.7% (48/72) vs. 22.2% (16/72), P < 0.01], and the 28-day survival rate was 9.8% [91.7% (66/72) vs. 81.9% (59/72), P < 0.01]. There was no significant difference in the combination of antiviral drugs, antibiotics, anticoagulants and vasopressor drugs between the two groups. There was no significant difference in the incidence of adverse events between the Xuebijing group and standard treatment group [41.7% (30/72) vs. 43.1% (31/72), P > 0.05], and no serious adverse events and adverse reactions of Xuebijing were reported.
CONCLUSIONS: Standard treatment combined with Xuebijing injection can significantly improve the PSI risk score and clinical prognosis of patients with severe COVID-19 without increasing drug safety risk.
参考来源
- Liu X, Song Y, Guan W, et al. [A multicenter prospective cohort study of Xuebijing injection in the treatment of severe coronavirus disease 2019]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2021. PMID: 34412743. doi:10.3760/cma.j.cn121430-20210514-00714
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。